诺唯赞: 2025年半年度报告摘要

Company Overview - Nanjing Novogene Bioinformatics Technology Co., Ltd. is listed on the Shanghai Stock Exchange with the stock code 688105 [1] - The company reported total assets of approximately 5.24 billion RMB, reflecting a 3.81% increase compared to the previous year [1] Financial Performance - The company's operating revenue for the reporting period was approximately 606.22 million RMB, a decrease of 6.63% compared to the same period last year [1] - The total profit for the period was reported as -9.65 million RMB, indicating a significant loss compared to a profit of -229,910.26 RMB in the previous year [1] - The net profit attributable to shareholders of the listed company was -33.14 million RMB, worsening from -15.29 million RMB year-on-year [1] Shareholder Information - As of the reporting period, the total number of shareholders was 8,596 [2] - The largest shareholder, Nanjing Novogene Investment Management Co., Ltd., holds 7.78% of the shares, amounting to 30,957,960 shares [2] - Other significant shareholders include Yang Qi with 5.50% and Cao Lin with 5.38% of the shares [2] Research and Development - The company has invested in research and development, although specific percentages of revenue allocated to R&D were not detailed in the provided excerpts [2]